Vital microscopic analysis of polymeric micelle extravasation from tumor vessels: Macromolecular delivery according to tumor vascular growth stage

Journal of Pharmaceutical Sciences

Volumn 99, Issue 1, 2010, Pages 549-562

  Hori, Katsuyoshi ^a   Nishihara, Masamichi ^b   Yokoyama, Masayuki ^b  

^a TOHOKU UNIVERSITY   (Japan)

^b KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Cancer; Cancer chemotherapy; Drug targeting; EPR effect; Macromolecular drug delivery; Micelle; Permeability; Polymeric drug carrier; Tumor vessels; Vital microscopy

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IMAGE ANALYSIS; MALE; MICELLE; MICROANALYSIS; NONHUMAN; RAT; TISSUE NECROSIS; TUMOR GROWTH; VASCULAR TUMOR; YOSHIDA SARCOMA;

EID: 73949137806     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21848     Document Type: Article

References (39)

1. Matsumura Y, Maeda H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392.
2. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. 2000. Tumor vascular permeability and EPR effect for macromolecular therapeutics. J Control Release 65:271-284.
3. Ferrari M. 2005. Cancer nanotechnology: Opportunity and challenges. Nat Rev Cancer 5:161-171.
4. Duncan R. 2006. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6:688-701.
5. Greish K. 2007. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J Drug Target 15:457-464.
6. Matsumura Y. 2008. Poly(amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev 60:899-914.
7. Lammers T, Hennink WE, Storm G. 2008. Tumourtargeted nanomedicines: Principles and practice. Br J Cancer 99:392-397.
8. Campbell RB, Ying BO, Kuesters GM, Hemphill R. 2009. Fighting cancer: From the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 98:411-429.
9. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
10. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR. 1991. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 174:1275-1278.
11. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med 9:669-676. 12. Long DM. 1970. Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg 32:127-144.
12. Roberts WG, Palade GE. 1997. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57:765-772.
13. Feng D, Nagy JA, Hipp J, Dvorak HF, Dvorak AM. 1996. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 183:1981-1986.
14. Yamaura H, Sato H. 1974. Quantitative studies on the developing vascular system of rat hepatoma. J Natl Cancer Inst 53:1229-1240.
15. Warren BA. 1979. The vascular morphology of tumors. In: Peterson HI, editor. Tumor blood circulation. Boca Raton, FL: CRC Press. pp. 1-47.
16. Hori K, Saito S, Sato Y, Akita H, Kawaguchi T, Sugiyama K, Sato H. 2003. Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs: Implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Eur J Cancer 39:1957-1966.
17. Hori K, Suzuki M, Abe I, Saito S. 1986. Increased tumor tissue pressure in association with the growth of rat tumors. Jpn J Cancer Res 77:65-73.
18. Yokoyama M. 2005. Polymeric micelles for the targeting hydrophobic drugs. In: Kwon GS, editor. Drug and pharmaceutical sciences, Vol. 148, Polymeric drug delivery systems. Boca Raton, FL: Taylor & Francis. pp. 533-575.
19. Aliabadi HM, Lavasanifar A. 2006. Polymeric micelles for drug delivery. Expert Opin Drug Deliv 3:139-162.
20. Yokoyama M, Okano T, Sakurai Y, Fukushima S, Okamoto K, Kataoka K. 1999. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. J Drug Target 7:171-186.
21. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T. 2005. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumor activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 92:1240-1246.
22. Liu B, Yang M, Li X, Qian X, Shen Z, Ding Y, Yu L. 2008. Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer. J Pharm Sci 97:3170-3181.
23. Cabral H, Nishiyama N, Kataoka K. 2007. Optimization of (1,2-diamino-cyclohexane) platinum (II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J Control Release 121:146-155.
24. Yokoyama M, Opanasopit P, Maitani Y, Kawano K, Okano T. 2004. Polymer design and incorporation method for polymeric micelle carrier system containing water-insoluble anti-cancer agent camptothecin. J Drug Target 12:373-384.
25. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, Matsumura Y. 2006. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 66:10048-10056.
26. Shiraishi K, Kawano K, Minowa T, Maitani Y, Yokoyama M. Preparation and in vivo imaging of PEG-poly(L-lysine)-based polymeric micelle MRI contrast agents. J Control Release (in press).
27. Yamaura H, Suzuki M, Sato H. 1971. Transparent chamber in the rat skin for studies on microcirculation in cancer tissue. Gann 62:177-185.
28. Hori K, Suzuki M, Tanda S, Saito S. 1990. In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res 81:279-288.
29. Thomlinson RH, Gray LH. 1955. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539-549.
30. Hori K, Furumoto S, Kubota K. 2008. Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth. Cancer Sci 99:1485-1491.
31. Popovic V, Popovic P. 1960. Permanent cannulation of aorta and vena cava in rats and ground squirrels. J Appl Physiol 15:727-728.
32. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y. 1999. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90:1026-1038.
33. Chen B, Pogue BW, Luna JM, Hardman RL, Hoopes PJ, Hasan T. 2006. Tumor vascular permeabilization by vascular-targeting photosensitization: Effects, mechanism, and therapeutic implications. Clin Cancer Res 12:917-923.
34. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. 2006. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 98:335-344.
35. He C, Agharkar P, Chen B. 2008. Intravital microscopic analysis of vascular perfusion and macromolecule extravasation after photodynamic vascular targeting therapy. Pharm Res 25:1873-1880.
36. Yamaura H, Matsuzawa T. 1979. Tumour regrowth after irradiation. An experimental approach. Int J Radiat Biol 35:201-219.
37. Ji RC. 2006. Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev 25:677-694.
38. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK. 2002. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296:1883-1886.
39. Pathak AP, Artemov D, Ward BD, Jackson DG, Neeman M, Bhujwalla ZM. 2005. Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res 65:1425-1432.